t
Trellus Health plc announced on January 20, 2026, that all resolutions presented at its General Meeting held earlier that day were duly passed on a poll. Resolution 1 (Ordinary) received 99.90% of votes in favour, Resolution 2 (Special) received 99.89% in favour, and Resolution 3 (Ordinary) received 99.90% in favour. Special Resolutions 4 and 5 both passed with 99.87% of votes in favour.
| Date | 20 Jan 2026 |
| Time | 14:00:01 |
| Category | AGMs and other meetings |
| ID | 6378P |
Trellus Health plc
("Trellus Health", the "Company" or the "Group")
Result of General Meeting
LONDON, U.K. AND NEW YORK, U.S. (20 January 2026). Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that at the General Meeting ("GM") held earlier today, all resolutions, as set out in the GM notice published on 31 December 2025, were duly passed on a poll.
The voting results of the GM were as follows:
|
|
|
In Favour |
Against |
Withheld |
||
|
Resolution |
Type |
Votes |
% |
Votes |
% |
Votes |
|
1 |
Ordinary |
68,221,782 |
99.90 |
71,031 |
0.10 |
4,625 |
|
2 |
Special |
68,217,291 |
99.89 |
76,004 |
0.11 |
4,143 |
|
3 |
Ordinary |
68,221,782 |
99.90 |
71,031 |
0.10 |
4,625 |
|
4 |
Special |
68,206,212 |
99.87 |
87,083 |
0.13 |
4,143 |
|
5 |
Special |
68,206,212 |
99.87 |
87,083 |
0.13 |
4,143 |
For further information please contact:
|
Trellus Health plc |
||
|
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder |
Via Walbrook PR |
|
|
Joy Bessenger, Chief Financial Officer |
|
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and Broker) |
Tel: +44 (0)20 7496 3000 |
|
|
Philip Davies / James Todd / Patrick Weaver |
|
|
|
|
|
|
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
|
Paul McManus / Lianne Applegarth / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/ +44 (0)7407 804 654 |
|
About Trellus Health plc (www.trellushealth.com)
Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.
Trellus Health also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.
The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.
Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com